Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. https://doi.org/10.3322/caac.21660.

Article  PubMed  Google Scholar 

Tomasetti C, Vogelstein B. Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science. 2015;347(6217):78–81. https://doi.org/10.1126/science.1260825.

Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

Jiralerspong S, Goodwin PJ. obesity and breast cancer prognosis: evidence, challenges, and opportunities. J Clin Oncol. 2016;34(35):4203–16.

Article  CAS  PubMed  Google Scholar 

Pérez-Solis MA, Maya-Nuñez G, Casas-González P, et al. Effects of the lifestyle habits in breast cancer transcriptional regulation. Cancer Cell Int. 2016;13(16):7. https://doi.org/10.1186/s12935-016-0284-7.

Article  CAS  Google Scholar 

Fiocchetti M, Bastari G, Cipolletti M, et al. The peculiar estrogenicity of diethyl phthalate: modulation of estrogen receptor Α activities in the proliferation of breast cancer cells. Toxics. 2021;9:237.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Darbre PD. Endocrine disrupting chemicals and breast cancer cells. Adv Pharmacol. 2021;92:485–520.

Article  CAS  PubMed  Google Scholar 

• Sarhangi N, Hajjari S, Heydari SF, et al. Breast cancer in the era of precision medicine. Mol Biol Rep. 2022;49(10):10023–37. https://doi.org/10.1007/s11033-022-07571-2. (This study highlights the therapeuthic approach to breast cancer according to the various molecular subtypes. It describes also treatment sequences which are fundamental to plan the best treatment path for each patient.)

Article  CAS  PubMed  Google Scholar 

Schmid P, Cortes J, Pusztai L, McArthur H, et al. Pembrolizumab for early triple-negative breast cancer. N Engl J Med. 2020;382:810–21. https://doi.org/10.1056/NEJMoa1910549.

Article  CAS  PubMed  Google Scholar 

Gianni L, Pienkowski T, Im Y-H, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial. Lancet Oncol. 2016;17(6):791–800. https://doi.org/10.1016/S1470-2045(16)00163-7.

Article  CAS  PubMed  Google Scholar 

von Minckwitz G, Huang C-S, Mano MS, Loibl S, et al. Trastuzumab emtansine for residual invasive HER2-positive breast cancer. N Engl J Med. 2019;380:617–28. https://doi.org/10.1056/NEJMoa1814017.

Article  Google Scholar 

Masuda N, Lee S-J, Ohtani S, Im Y-H, et al. Adjuvant capecitabine for breast cancer after preoperative chemotherapy. N Engl J Med. 2017;376:2147–59. https://doi.org/10.1056/NEJMoa1612645.

Article  CAS  PubMed  Google Scholar 

von Minckwitz G, Procter M, de Azambuja E, Zardavas D, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017;377:122–31. https://doi.org/10.1056/NEJMoa1703643.

Article  Google Scholar 

Geyer CE Jr, Garber JE, Gelber RD, et al. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer. Ann Oncol. 2022;33(12):1250–68. https://doi.org/10.1016/j.annonc.2022.09.159.

Article  CAS  PubMed  Google Scholar 

Johnston SRD, Toi M, O’Shaughnessy J, Rastogi P, et al. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. The Lancet Oncology. 2022. https://doi.org/10.1016/S1470-2045(22)00694-5.

Article  PubMed  Google Scholar 

Cortes J, Rugo HS, Cescon DW, Im S-A, et al. Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med. 2022;387:217–26. https://doi.org/10.1056/NEJMoa2202809.

Article  CAS  PubMed  Google Scholar 

Emens LA, Adams S, Barrios CH, Diéras V, et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. Ann Oncol. 2021;32(8):983–93. https://doi.org/10.1016/j.annonc.2021.05.355.

Article  CAS  PubMed  Google Scholar 

Swain SM, Miles D, Kim S-B, Im Y-H, et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol. 2020. https://doi.org/10.1016/S1470-2045(19)30863-0.

Article  PubMed  Google Scholar 

Hurvitz SA, Hegg R, Chung W-P, Im S-A, et al. Trastuzumab deruxtecan versus trastuzumab emtansine in patients with HER2-positive metastatic breast cancer: updated results from DESTINY-Breast03, a randomised, open-label, phase 3 trial. Lancet. 2022. https://doi.org/10.1016/S0140-6736(22)02420-5.

Article  PubMed  Google Scholar 

Bardia A, Hurvitz SA, Tolaney SM, Loirat D, et al. Sacituzumab govitecan in metastatic triple-negative breast cancer. N Engl J Med. 2021;384:1529–41. https://doi.org/10.1056/NEJMoa2028485.

Article  CAS  PubMed  Google Scholar 

Di Lauro V, Barchiesi G, Martorana F, et al. Health-related quality of life in breast cancer patients treated with CDK4/6 inhibitors: a systematic review. ESMO Open. 2022;7(6):100629. https://doi.org/10.1016/j.esmoop.2022.100629.

Article  PubMed  PubMed Central  Google Scholar 

Mertz S, Benjamin C, Girvalaki C, et al. Progression-free survival and quality of life in metastatic breast cancer: the patient perspective. Breast. 2022;65:84–90. https://doi.org/10.1016/j.breast.2022.07.006.

Article  PubMed  PubMed Central  Google Scholar 

Brown JC, Ligibel JA. Lifestyle interventions for breast cancer prevention. Curr Breast Cancer Rep. 2018;10(3):202–8. https://doi.org/10.1007/s12609-018-0281-z.

Article  PubMed  PubMed Central  Google Scholar 

Orman A, Johnson DL, Comander A, Brockton N. Breast cancer: a lifestyle medicine approach. Am J Lifestyle Med. 2020;14(5):483–94. https://doi.org/10.1177/1559827620913263.

Article  PubMed  PubMed Central  Google Scholar 

Kayl AE, Meyers CA. Side-effects of chemotherapy and quality of life in ovarian and breast cancer patients. Curr Opin Obs Gynecol. 2006;18:24–8.

Article  Google Scholar 

De Cicco P, Catani MV, Gasperi V, Sibilano M, et al. Nutrition and breast cancer: a literature review on prevention, treatment and recurrence. Nutrients. 2019;11(7):1514. https://doi.org/10.3390/nu11071514.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Boltong A, Aranda S, Keast R, Wynne R, et al. A prospective cohort study of the effects of adjuvant breast cancer chemotherapy on taste function, food liking, appetite and associated nutritional outcomes. PLoS ONE. 2014;9:e103512.

Article  ADS  PubMed  PubMed Central  Google Scholar 

Buch K, Gunmalm V, Andersson M, Schwarz P, et al. Effect of chemotherapy and aromatase inhibitors in the adjuvant treatment of breast cancer on glucose and insulin metabolism-a systematic review. Cancer Med. 2019;8:238–45.

Article  PubMed  Google Scholar 

Irwin ML, McTiernan A, Baumgartner RN, Baumgartner KB, et al. Changes in body fat and weight after a breast cancer diagnosis: Influence of demographic, prognostic, and lifestyle factors. J Clin Oncol. 2005;23:774–82.

Article  PubMed  Google Scholar 

Ee C, Cave A, Vaddiparthi V, Naidoo D, Boyages J. Factors associated with weight gain after breast cancer: results from a community-based survey of Australian women. Breast. 2023;S0960–9776(23):00012–7. https://doi.org/10.1016/j.breast.2023.01.012.

Article  Google Scholar 

Vance V, Mourtzakis M, McCargar L, Hanning R. Weight gain in breast cancer survivors: prevalence, pattern and health consequences. Obes Rev. 2011;12(4):282–94. https://doi.org/10.1007/s12282-022-01355-z.

Article  CAS  PubMed  Google Scholar 

Wong RMY, Wong H, et al. The relationship between sarcopenia and fragility fracture-a systematic review. Osteoporos Int. 2019;30(3):541–53. https://doi.org/10.1007/s00198-018-04828-0.

Article  CAS  PubMed  Google Scholar 

World Cancer Research Fund/American Institute for Cancer Research. Diet, nutrition, physical activity and cancer: a global perspective. Continuous Update Project Expert Report 2018. Available at https://www.wcrf.org/wp-content/uploads/2021/02/Summary-of-Third-Expert-Report-2018

Campbell JN, Barton C, Cutress RI, Copson ER. Impact of obesity, lifestyle factors and health interventions on breast cancer survivors. Proc Nutr Soc. 2023;82(1):47–57. https://doi.org/10.1017/S0029665122002816.

Article  PubMed  Google Scholar 

Meyer D, Pastor-Villaescusa B, Michel S, Hauner H, Hauner D. Associations between circulating obesity-related biomarkers and prognosis in female breast cancer survivors: a systematic review of observational data in women enrolled in lifestyle intervention trials. BMC Cancer. 2022;22(1):1187. https://doi.org/10.1186/s12885-022-10274-3.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Lake B, Damery S, Jolly K. Effectiveness of weight loss interventions in breast cancer survivors: a systematic review of reviews. BMJ Open. 2022;12(10):e062288. https://doi.org/10.1136/bmjopen-2022-062288.

Article  PubMed  PubMed Central